Jefferies Financial Group began coverage on shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) in a research note issued to investors on Monday morning,Zacks reports. The firm issued a strong-buy rating on the stock.
A number of other equities analysts have also recently commented on the stock. Weiss Ratings cut shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. HC Wainwright reiterated a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Aligos Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $38.50.
View Our Latest Stock Analysis on ALGS
Aligos Therapeutics Stock Down 16.0%
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($2.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.19. The company had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $4.85 million. Aligos Therapeutics had a negative return on equity of 206.30% and a negative net margin of 197.01%. As a group, sell-side analysts anticipate that Aligos Therapeutics will post -6.61 EPS for the current fiscal year.
Hedge Funds Weigh In On Aligos Therapeutics
Several institutional investors have recently bought and sold shares of ALGS. Renaissance Technologies LLC raised its position in Aligos Therapeutics by 17.6% during the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock worth $746,000 after buying an additional 15,006 shares during the last quarter. SummitTX Capital L.P. raised its holdings in Aligos Therapeutics by 6.7% during the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after purchasing an additional 9,375 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Aligos Therapeutics by 1,652.8% during the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after purchasing an additional 216,646 shares in the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.
Aligos Therapeutics Company Profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections. Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.
See Also
- Five stocks we like better than Aligos Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
